TCT-443 Multiplug Paravalvular Leak Closure Using Amplatzer Vascular Plug III – Prospective Registry (Wizzard I)  by Smolka, Grzegorz A. et al.
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comand BVS (p< 0.05)(Figure). The number of platelet aggregation clots was the
least in Synergy DES with a borderline signiﬁcant difference compared to other
stents.Conclusions: The current ex vivo swine shunt model demonstrated decreased acute
thrombogenicity in bioerodible polymer thin-strut Synergy as compared to bioerodible
thick-strut Biomatrix Flex and fully bioresorbable Absorb, which conﬁrms the acute
protective function of bioerodible stent coatings and emphasizes the relevance of stent
geometry in acute thrombogenicity.
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Background: Transcatheter paravalvular leak closure (TPVLC) has become a viable
alternative to reoperation but optimal technical strategy is still to be deﬁned. We
present a prospective TPVLC registry in which safety and efﬁcacy of multi-plug,
single-stage approach were assessed.
Methods: All subjects presented with hemodynamically signiﬁcant PVL and
symptomatic heart failure (HF). Decision on performing TPVLC was made by
the Heart Team and procedures were executed in hybrid operating room. Ante-
or retrograde access was employed for mitral while retrograde only for aortic
PVLs. 2 to 4 AVP 3 devices (size and number based on PVL channel cross-
sectional area by real-time three-dimensional transesophageal echocardiogra-
phy) were simultaneously implanted into a single PVL channel. Endpoints
were deﬁned according to VARC-2 and modiﬁed if demanded by TPVLC
speciﬁcity.
Results: Enrollment started in 2010 and reported data is complete as of December
2013. From 64 referred patients 49, with either mechanical valves (n¼30) or
stented bioprostheses, were found eligible for TPVLC. PVL location was mitral
(n¼29) or aortic. In the aortic group acute procedural success (APS) ratio was
100% and no MACCEs occurred. In the mitral group, TPVLC was successful on
ﬁrst attempt in 22 cases (4/4 in transapical and 18/25 in transseptal access).
Following transseptal failure another transapical procedure was performed in 5
patients. TPVLC ultimately proved efﬁcient in 89.7% of mitral PVLs with APS
of 76.5%. Cumulatively, TPVLC was accomplished in 46 subjects (93.9%) with
APS of 78%. When successful, it led to signiﬁcant decrease of NT-proBNP
concentration and HF symptoms regression. Safety endpoints were met in 4 pa-
tients and included non-disabling stroke (transient aphasia), plug embolization
(successfully snared) and 2 access site-related complications. In device failure
group 2 deaths occurred (end-stage HF) and 2 other patients were rehospitalized
(decompensated HF).
Conclusions: Multi-plug, single-stage TPVLC with use of AVP III devices is
effective and safe strategy in patients with hemodynamically signiﬁcant PVL. It ap-
pears exceptionally well suited for aortic PVLs.B130 JACC Vol 64/11/Suppl B jTCT-444
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Background: Transduction efﬁcacy, delivery approaches and vector serotypes are
representing major challenges for future cardiac gene therapy. The aim of this current
study was to test not only the anterograde coronary approach for gene delivery but
three different AAV serotypes (6, 7 and 9) in a pre-clinical large animal model.
Methods: The approach was tested in 19 chronically instrumented dogs which
received the AAV vectors anterograde intracoronarily. The left main coronary artery
was cannulated with a Cobra1 catheter (5F) and a micro-infusion catheter (2.5F) was
selectively advanced into LAD and RCX. The solution for infusion was prepared with
normal saline, 1x10
ˇ
13 AAV-(6, 7 or 9)-eGFP particles, SubstanceP (0.25-0.5ng/kg/
min) and Adenosine (0.15mg/kg/min) and was injected slowly over 20min. Nitro-
glycerine was given i.v. (1mg/kg/min) to further enhance endothelial penetration of the
virus. The coronary sinus was approached with a custom made balloon in eleven
subjects. Hemodynamic data were recorded and infection efﬁcacy was assessed using
immunohistochemistry for eGFP after 30days.
Results: Procedure time was signiﬁcantly longer in the cases with coronary sinus
occlusion (6010 vs. 9045min, p< 0.05). Mean arterial pressure and dP/dtmax
dropped in all cases due to the vasodilators (11815 to 5321mmHg and
2289466 to 1421414mmHg/sec). These effects were enhanced with coronary
sinus blockage that infusion had to be discontinued several times due to hypo-
tension. The eGFP-transduction rate with AAV9 was heterogeneous within the
myocardial layers (0.3-56%), with a higher transduction in the subendocardial
layer (22-45%).There was no signiﬁcant increase of eGFP-expression caused by
the additional coronary sinus blockage (p¼0.07). Comparing the different sero-
types AAV7 and AAV9 have been more effective infecting LV tissue than AAV6
(167%, 219% vs. 42%, p< 0.05).
Conclusions: Anterograde cardiac gene delivery is feasible and comparatively
effective. The addition of coronary sinus blockage did not increase efﬁciency
signiﬁcantly. Individual characteristics need to be taken into account selecting the
optimal AAV serotype for translatable results.
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Background: The deployment of the stent sometimes associates with difﬁculty
because of the unfavorable lesion characteristics including severe calciﬁcation or
tortious conﬁguration of the vessel, and insufﬁcient backup support of the guiding
catheter. To address this issue, the small-sized straight inner catheter have been
developed to access the lesion, where the stent to be implanted. Recently, a novel
4.5-Fr child catheter with hyper lubricity in outer surface to ease advancement of the
catheter was developed to improve the success rate in stent delivery.
Methods: We retrospectively evaluated 51 consecutive patients, who underwent
primary percutaneous coronary intervention with CoKatte catheter (Asahi Intecc
Co.,Ltd, Seto, Japan) after failure in delivering the stents with conventional procedure
with 6-Fr guiding catheter between January 2011 and December 2013. CoKatte
catheter is a straight catheter with 1.5mm in outer diameter, 120 cm in length, and
compatible for 6-Fr guide catheter.
Results: The mean age of the patients was 75.3 years old and 29 male patients were
included. Target vessels were comprised of 13 LADs, 7 LCXs, 27 RCAs, and 4 SVGs.
Trans-radial approach was performed in 41 patients. Six lesions were chronic total
occlusion. Seven lesions required the lesion preparation with Rotablator (Boston
Scientiﬁc Corp.) before stent delivery. For advancement and subsequent deep intu-
bation of the catheter, anchor balloon technique was needed in 42 patients, otherwise,
the catheter could be advanced under support of the guide wire or the shaft of the
balloon catheter. In all cases, stent delivery in the intended lesion was achieved. The
complication related to deep insertion of the catheter including proximal dissection, air
embolism, and severe ischemia were not observed.
Conclusions: This novel 4.5-Fr catheter is considered to contribute for facilitating
stent delivery in the complex lesion in the coronary arteries.September 13–17, 2014 j TCT Abstracts/New Devices and Innovation
